Kelly Westbrook

Duke Medical Center — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

14h-index608citations52works1.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Breast Cancer Treatment Studies(14), Advanced Breast Cancer Therapies(10), Cancer survivorship and care(9), HER2/EGFR in Cancer Research(9), Cancer Treatment and Pharmacology(9)

Publications52 total

Abstract P1-02-04: Impact of abemaciclib dose escalation on compliance and safety in hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer
Clinical Cancer Research·2025· 1 cited
Abstract P2-12-01: Survival Outcomes after Pathologic Complete Response with Neoadjuvant Endocrine Therapy vs. Neoadjuvant Chemotherapy
Clinical Cancer Research·2025
Survival outcomes after pathologic complete response with neoadjuvant endocrine therapy vs. neoadjuvant chemotherapy: a retrospective national database study
Breast Cancer Research and Treatment·2025· 2 cited
Web-Based Pain Coping Skills Training (PCST) for Managing Aromatase Inhibitor-Associated Arthralgia in Breast Cancer Survivors: Randomized Controlled Trial Protocol
Contemporary Clinical Trials·2024Open Access
Efficacy of a couple‐based intervention addressing sexual concerns for breast cancer survivors: Results of a randomized controlled trial
Cancer·2024· 4 citedOpen Access
Examining inequities associated with incarceration among breast cancer patients
Cancer Medicine·2024· 4 citedOpen Access
The CROWN study: Cardiac outcomes with near-complete estrogen deprivation.
Journal of Clinical Oncology·2024
Assessment of efficacy and safety of dose-dense doxorubicin and cyclophosphamide (ddAC) in combination with immunotherapy in early-stage triple-negative breast cancer
Breast Cancer Research and Treatment·2024· 3 citedOpen Access
Abstract PO5-12-12: Implementation of a comprehensive monitoring protocol for the prevention and treatment of interstitial lung disease in patients undergoing treatment with trastuzumab deruxtecan
Cancer Research·2024
Abstract RF02-06: AVIATOR/TBCRC045: A randomized phase II study of vinorelbine (N) + trastuzumab (H) alone or combined with avelumab (A) +/- utomilumab (U) in patients (pts) with HER2+ metastatic breast cancer (MBC) (NCT03414658)
Cancer Research·2024
Abstract PO4-12-12: An Updated analysis of risk factor identification and Hyperglycemia prevention with alpelisib + fulvestrant in PIKC3A-mutated, hormone-receptor positive, human epidermal growth factor-2 negative advanced breast cancer
Cancer Research·2024
Web-Based Pain Coping Skills Training (Pcst) for Managing Aromatase Inhibitor-Associated Arthralgia in Breast Cancer Survivors: Randomized Controlled Trial Protocol
SSRN Electronic Journal·2024Open Access
Cardiovascular impact of near complete estrogen deprivation in premenopausal women with breast cancer: The CROWN study
American Heart Journal·2023· 2 citedOpen Access
Assessment of efficacy and safety of dose-dense doxorubicin and cyclophosphamide (ddAC) in combination with pembrolizumab in early-stage, triple-negative breast cancer.
Journal of Clinical Oncology·2023
Real-World Perspectives and Practices for Pneumonitis/Interstitial Lung Disease Associated With Trastuzumab Deruxtecan Use in Human Epidermal Growth Factor Receptor 2–Expressing Metastatic Breast Cancer
JCO Oncology Practice·2023· 66 citedOpen Access
Abstract P6-05-51: Best Quality of Care from a Distance (BQual-D): Maintaining high quality care for hormone receptor positive (HR+) metastatic breast cancer (MBC) during the COVID pandemic, patient participation and satisfaction with the program
Cancer Research·2023
ASO Visual Abstract: Survival Benefit of Chemotherapy According to 21-Gene Recurrence Score in Young Women with Breast Cancer
Annals of Surgical Oncology·2023
Survival Benefit of Chemotherapy According to 21-Gene Recurrence Score in Young Women with Breast Cancer
Annals of Surgical Oncology·2023· 4 cited
Evaluation of alpelisib-induced hyperglycemia prophylaxis and associated risk factors in PIK3CA-mutated hormone-receptor positive, human epidermal growth factor-2 negative advanced breast cancer
Breast Cancer Research and Treatment·2022· 7 cited
Evaluation of alpelisib-induced hyperglycemia prophylaxis and associated risk factors in PIK3CA-mutated hormone-receptor positive, human epidermal growth factor-2 negative advanced breast cancer
Research Square (Research Square)·2022Open Access
page 1 of 3Next →

Frequent Co-authors

Jeremy Force(14), Susan Dent(11), Gretchen Kimmick(9), Jennifer K. Plichta(9), Heather Moore(8), Sarah Sammons(8), Terry Hyslop(7), Laura S. Porter(6), Francis J. Keefe(6), Samantha M. Thomas(6), Carey K. Anders(6), Gloria Broadwater(5), Laura H. Rosenberger(5), Rebecca A. Shelby(5), P. Kelly Marcom(4), Kimberly Blackwell(4), Sarah Burnette(4), Emily Poehlein(4), Hui‐Jie Lee(4), Maggie L. DiNome(4)